Pascal Delsart

Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial

Michel Azizi, Marc Sapoval, Philippe Gosse et al. · The Lancet · 2015 · 508 citations

Non-pharmacological Intervention, Hypertension, Urology +11

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

Michel Azizi, Kintur Sanghvi, Manish Saxena et al. · The Lancet · 2021 · 375 citations · Full text

Hypertension, Urology, Renal Function +9

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial

Michel Azizi, Héléna Pereira, Idir Hamdidouche et al. · Circulation · 2016 · 153 citations

SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk

Stéphane Laurent, Gilles Châtellier, Michel Azizi et al. · Hypertension · 2021 · 110 citations · Full text

Visual Language, Hypertension, Kinesiology +14